Page 139 - Read Online

Page 42 Melnik et al. J Transl Genet Genom 2022;6:1-45 https://dx.doi.org/10.20517/jtgg.2021.37

classifications (last updated 2020-03-03) [Last accessed on 17 Dec 2021].
544. Marchese S, Polo A, Ariano A, Velotto S, Costantini S, Severino L. Aflatoxin B1 and M1: biological properties and their
involvement in cancer development. Toxins (Basel) 2018;10:214. DOI PubMed PMC
545. Vaz A, Cabral Silva AC, Rodrigues P, Venâncio A. Detection methods for aflatoxin M1 in dairy products. Microorganisms
2020;8:246. DOI PubMed PMC
546. Nguyen T, Flint S, Palmer J. Control of aflatoxin M in milk by novel methods: a review. Food Chem 2020;311:125984. DOI
1
PubMed
547. Scaglioni PT, Becker-Algeri T, Drunkler D, Badiale-Furlong E. Aflatoxin B and M in milk. Anal Chim Acta 2014;829:68-74. DOI
1 1
PubMed
548. Smith ER, Hagopian M. Uptake and secretion of carcinogenic chemicals by the dog and rat prostate. Prog Clin Biol Res
1981;75B:131-63. PubMed
549. Nishi N, Shoji H, Miyanaka H, Nakamura T. Androgen-regulated expression of a novel member of the aldo-keto reductase
superfamily in regrowing rat prostate. Endocrinology 2000;141:3194-9. DOI PubMed
550. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 2007;47:263-92. DOI
PubMed
551. Knight LP, Primiano T, Groopman JD, Kensler TW, Sutter TR. cDNA cloning, expression and activity of a second human aflatoxin
B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. Carcinogenesis 1999;20:1215-23. DOI PubMed
552. Yepuru M, Wu Z, Kulkarni A, et al. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes
prostate cancer growth. Clin Cancer Res 2013;19:5613-25. DOI PubMed
553. Karunasinghe N, Ambs S, Wang A, et al. Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529
polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts. PLoS One
2018;13:e0199122. DOI PubMed PMC
554. Karunasinghe N, Symes E, Gamage A, et al. Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological,
lifestyle and clinical features in a prostate cancer cohort from New Zealand. PLoS One 2019;14:e0217373. DOI PubMed PMC
555. Cui A, Hua H, Shao T, et al. Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration. Tumour Biol
2015;36:6507-13. DOI PubMed
556. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev
2010;36:177-84. DOI PubMed
557. Posadas EM, Ahmed RS, Karrison T, et al. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: a
University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate 2016;76:286-
93. DOI PubMed PMC
558. Li W, Wang Z, Wang L, et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate
cancer cells. Int J Clin Exp Med 2015;8:6563-7. PubMed PMC
559. Chakraborty G, Patail NK, Hirani R, et al. Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality
in BRCA2-altered prostate tumors. Clin Cancer Res 2021;27:1792-806. DOI PubMed PMC
560. Francis JC, Swain A. Prostate organogenesis. Cold Spring Harb Perspect Med 2018;8:a030353. DOI PubMed PMC
561. Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol
2003;253:165-74. DOI PubMed
562. Staack A, Donjacour AA, Brody J, Cunha GR, Carroll P. Mouse urogenital development: a practical approach. Differentiation
2003;71:402-13. DOI PubMed
563. Thomson AA, Marker PC. Branching morphogenesis in the prostate gland and seminal vesicles. Differentiation 2006;74:382-92.
DOI PubMed
564. Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL. Evidence that insulin-like growth factor I and growth hormone are required
for prostate gland development. Endocrinology 1999;140:1984-9. DOI PubMed
565. Kleinberg DL, Ruan W, Yee D, Kovacs KT, Vidal S. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development:
IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice. Endocrinology 2007;148:1080-8. DOI
PubMed
566. Ohlson N, Bergh A, Persson ML, Wikström P. Castration rapidly decreases local insulin-like growth factor-1 levels and inhibits its
effects in the ventral prostate in mice. Prostate 2006;66:1687-97. DOI PubMed
567. Ohlsson C, Mohan S, Sjögren K, et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009;30:494-535. DOI
PubMed PMC
568. Banjac L, Kotur-Stevuljević J, Gojković T, Bokan-Mirković V, Banjac G, Banjac G. Relationship between insulin-like growth factor
type 1 and intrauterine growth. Acta Clin Croat 2020;59:91-6. DOI PubMed PMC
569. Singal SS, Nygard K, Gratton R, Jansson T, Gupta MB. Increased insulin-like growth factor binding protein-1 phosphorylation in
decidualized stromal mesenchymal cells in human intrauterine growth restriction placentas. J Histochem Cytochem 2018;66:617-30.
DOI PubMed PMC
570. Agrogiannis GD, Sifakis S, Patsouris ES, Konstantinidou AE. Insulin-like growth factors in embryonic and fetal growth and skeletal
development (Review). Mol Med Rep 2014;10:579-84. DOI PubMed PMC
571. Ghosh S, Lau H, Simons BW, et al. PI3K/mTOR signaling regulates prostatic branching morphogenesis. Dev Biol 2011;360:329-42.
DOI PubMed PMC
572. Li Y, Ge C, Franceschi RT. Role of Runx2 in prostate development and stem cell function. Prostate 2021;81:231-41. DOI PubMed